Next Article in Journal
Introduction to Special Issue of Plant Virus Emergence
Next Article in Special Issue
Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design
Previous Article in Journal
Protein Disulfide Isomerase A4 Is Involved in Genome Uncoating during Human Astrovirus Cell Entry
Review

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval

Texas Tech University School of Veterinary Medicine, Amarillo, TX 79106, USA
Academic Editors: Kenneth Lundstrom and Alaa A. A. Aljabali
Viruses 2021, 13(1), 54; https://doi.org/10.3390/v13010054
Received: 8 December 2020 / Revised: 27 December 2020 / Accepted: 29 December 2020 / Published: 31 December 2020
(This article belongs to the Special Issue Vaccines and Therapeutics against Coronaviruses)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial cells by using the spike protein on its surface to bind to angiotensin-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I–III) and an additional 164 candidates are in preclinical stages. The efficacy data from phase I/II trials of lead candidate vaccines look very promising with virus-neutralizing geometric mean antibody titers in the range of 16.6–3906. Most recently, two SARS-CoV-2 candidate vaccines, BNT162b2 and mRNA-1273, have been granted the first emergency use authorization (EUA) in the U.S.; BNT162b2 has also been granted an EUA in the United Kingdom, Canada, and in the European Union. This review assesses whether SARS-CoV-2 candidate vaccines (with approved EUA or in phase III trials) meet the criteria for an ideal SARS-CoV-2 vaccine. The review concludes with expectations from phase III trials and recommendations for phase IV studies (post-vaccine approval). View Full-Text
Keywords: SARS-CoV-2; COVID-19; SARS-CoV-2 vaccines; clinical trials SARS-CoV-2; COVID-19; SARS-CoV-2 vaccines; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Tumban, E. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses 2021, 13, 54. https://doi.org/10.3390/v13010054

AMA Style

Tumban E. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2021; 13(1):54. https://doi.org/10.3390/v13010054

Chicago/Turabian Style

Tumban, Ebenezer. 2021. "Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval" Viruses 13, no. 1: 54. https://doi.org/10.3390/v13010054

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop